VASCOR Drug Patent Profile

Which patents cover Vascor, and when can generic versions of Vascor launch?

Vascor is a drug marketed by Johnson And Johnson and Mallinckrodt and is included in two NDAs.

The generic ingredient in VASCOR is iothalamate meglumine; iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate meglumine; iothalamate sodium profile page.

Summary for VASCOR

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	1
Patent Applications:	761
DailyMed Link:	VASCOR at DailyMed

Recent Clinical Trials for VASCOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Poznan University of Medical Sciences	Phase 3

See all VASCOR clinical trials

US Patents and Regulatory Information for VASCOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	VASCORAY	iothalamate meglumine; iothalamate sodium	INJECTABLE;INJECTION	016783-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-001	Dec 28, 1990		DISCN	No	No
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-002	Dec 28, 1990		DISCN	No	No
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-003	Dec 28, 1990		DISCN	No	No

Expired US Patents for VASCOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-001	Dec 28, 1990	RE30577
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-002	Dec 28, 1990	RE30577
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-003	Dec 28, 1990	RE30577

International Patents for VASCOR

See the table below for patents covering VASCOR around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	795735
Germany	2310918
Israel	41619	N-PROPANOLAMINE ETHERS AND THEIR PREPARATION
Netherlands	153190
United Kingdom	1377327

Market Dynamics and Financial Trajectory for VASCOR (Bepridil)

Introduction to VASCOR (Bepridil)

VASCOR (bepridil hydrochloride) is a calcium channel blocker used primarily to treat hypertension (high blood pressure) and angina (chest pain). Despite its therapeutic benefits, the drug has faced several challenges that impact its market dynamics and financial trajectory.

Therapeutic Uses

VASCOR is utilized for managing hypertension and angina by relaxing blood vessels and reducing the heart's workload, thereby improving blood flow and reducing chest pain[2].

Market Size and Growth

While specific market size data for VASCOR alone is not readily available, the broader market for cardiovascular disease drugs provides context. The global cardiovascular disease drugs market, which includes drugs like VASCOR, has seen significant growth. This market is driven by increasing prevalence of cardiovascular diseases, favorable regulatory environments, and government investments in healthcare infrastructure[4].

Regional Market Analysis

• North America: This region is expected to dominate the global cardiovascular disease drugs market due to a favorable regulatory environment and high prevalence of cardiovascular diseases. However, VASCOR's market share in this region is limited due to its withdrawal as an antihypertensive agent in the USA[4][5].
• Europe and Asia Pacific: These regions also show potential for growth in the cardiovascular disease drugs market, driven by increasing research and development activities and government initiatives. However, VASCOR's presence in these markets is restricted due to its limited approval and use.

Competitive Landscape

The competitive landscape for cardiovascular disease drugs is intense, with several other calcium channel blockers, beta blockers, and diuretics available. Drugs like Tracleer, Letairis, and existing calcium channel blockers have seen increased demand, making it challenging for VASCOR to gain significant market share[4].

Side Effects and Safety Concerns

VASCOR is associated with several side effects and safety concerns, which have significantly impacted its market dynamics. These include:

• Central Nervous System Effects: Dizziness, vertigo, akathisia, drowsiness, and tremor.
• Pro-arrhythmic Effects: Prolongation of QT and QTc intervals, leading to torsades de pointes type ventricular tachycardia.
• Hepatic Enzyme Elevation: Clinically significant transaminase elevations.
• Other Adverse Effects: Congestive heart failure, agranulocytosis, and hypokalemia[2].

Financial Performance

Given the safety concerns and limited market presence, VASCOR's financial performance is not as robust as other cardiovascular disease drugs. Here are some key financial implications:

• Withdrawal from US Market: VASCOR has been withdrawn as an antihypertensive agent in the USA, significantly reducing its revenue potential[5].
• Limited Use: Due to its side effects and safety concerns, VASCOR is reserved for patients where other anti-anginal agents are not effective, further limiting its market share.
• Comparative Sales: In comparison to other cardiovascular drugs, VASCOR's sales are likely to be lower due to its restricted use and safety profile.

Key Players and Market Strategies

While VASCOR is not a major player in the global cardiovascular disease drugs market, other key players such as Merck, Teva Pharmaceuticals, and Novartis dominate the market. These companies focus on developing drugs with better safety profiles and higher efficacy, which further marginalizes VASCOR's market position[1][4].

Future Outlook

The future outlook for VASCOR is challenging due to its safety concerns and limited market approval. The global cardiovascular disease drugs market is expected to grow, but VASCOR is unlikely to be a significant contributor to this growth.

Key Takeaways

• VASCOR is a calcium channel blocker with limited market presence due to safety concerns.
• The drug has been withdrawn from the US market as an antihypertensive agent.
• Its use is restricted to patients where other treatments are not effective.
• The financial performance of VASCOR is impacted by its limited market share and safety profile.
• The broader cardiovascular disease drugs market is growing, but VASCOR is not expected to be a major player.

FAQs

Q: What is VASCOR (bepridil) used for? A: VASCOR (bepridil) is used to treat hypertension (high blood pressure) and angina (chest pain).

Q: Why was VASCOR withdrawn from the US market? A: VASCOR was withdrawn from the US market as an antihypertensive agent due to its safety concerns, including pro-arrhythmic effects and other adverse reactions.

Q: What are the major side effects of VASCOR? A: Major side effects include dizziness, vertigo, akathisia, drowsiness, tremor, and pro-arrhythmic effects such as torsades de pointes type ventricular tachycardia.

Q: How does VASCOR compare to other cardiovascular disease drugs in terms of market share? A: VASCOR has a limited market share compared to other cardiovascular disease drugs due to its safety concerns and restricted use.

Q: What is the future outlook for VASCOR in the global cardiovascular disease drugs market? A: The future outlook for VASCOR is challenging, with the drug unlikely to be a significant contributor to the growth of the global cardiovascular disease drugs market.

Cited Sources

1. Verified Market Research - Bisoprolol Market Size, Share, Trends & Forecast
2. RxList - Vascor (Bepridil): Side Effects, Uses, Dosage, Interactions, Warnings
3. ASPE - Antimicrobial Drugs Market Returns Analysis
4. BioSpace - Cardiovascular Disease Drugs Market Outlook, Competitive Landscape and Forecasts to 2031
5. MDPI - Formulation, Stability, Pharmacokinetic, and Modeling Studies for Bepridil (Vascor)